Floatz logo

Ferumoxytol

DLBCL - Diffuse Large B Cell Lymphoma

Medical University of ViennaOtherEarly Phase 1Active
C
38/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
81/ 100

Competitive context

18 Active assets in the DLBCL - Diffuse Large B Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Glofitamab
National Cancer Institute (NCI)
Phase 3BB
Ari-0001
GUSTAVO SALGUERO
Phase 2B
Pirtobrutinib
The First Affiliated Hospital of Soochow University
Phase 2B
5-azacytidine
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2B
Dexrazoxane
Beth Israel Deaconess Medical Center
Phase 3B

View all 18 →

Same molecule, other indications

Ferumoxytol is also rated in:

cerebral atherosclerosisDormant
BB
Indicative ·
69 / 100
View asset →
glioblastomaDormant
B
Indicative ·
60 / 100
View asset →
multiple sclerosisDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →